- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioCryst Pharmaceuticals Inc (BCRX)
Assess today's live BioCryst Pharmaceuticals Inc (BCRX) share price, performance and insights using our live NASDAQ: BCRX stock exchange data.
Analyse the historical data and BioCryst Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on BioCryst share price buy/sell indicators using real-time data (or discuss the BioCryst (BCRX) stock price today with other investors in the BioCryst NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BCRX share price (ISIN: US09058V1035) to enhance your trading decisions with our free investment tools and resources.
What Is the BioCryst Pharmaceuticals Inc Share Price Today?
The BioCryst share price today is 7.530.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc
The stock symbol (or 'ticker') for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and BioCryst Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on BioCryst share price buy/sell indicators using real-time data (or discuss the BioCryst (BCRX) stock price today with other investors in the BioCryst NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ BCRX share price (ISIN: US09058V1035) to enhance your trading decisions with our free investment tools and resources.
What Is the BioCryst Pharmaceuticals Inc Share Price Today?
The BioCryst share price today is 7.530.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc
The stock symbol (or 'ticker') for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.445
7.640
52 wk Range
6.000
11.310
BCRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.4457.640
52 wk Range
6.00011.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
20.600
Upside
+173.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
BioCryst Company Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals Inc SWOT Analysis
Orladeyo's Triumph | BioCryst's flagship HAE treatment drives 41.67% revenue growth, with projected 2025 sales of $535-550 million, showcasing strong market performance |
Profitability on Horizon | Accelerated path to profitability expected by 2025, one year ahead of schedule, with analysts forecasting positive EPS and cash flow in 2026 |
Pipeline Potential | Explore BioCryst's strategic expansion into pediatric HAE treatment and development of novel therapies for Netherton syndrome and diabetic macular edema |
Market Dynamics | Analyst targets range from $8 to $20, reflecting diverse views on BioCryst's ability to navigate increasing competition and capitalize on pipeline opportunities |
BioCryst Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- BioCryst reported Q3 2025 EPS of $0.16, beating estimates by 220%, though revenue of $159.1 million fell short of expectations, causing a 3.89% stock decline.
- ORLADEYO revenue increased 37% year-over-year, with the company raising full-year guidance to $590-600 million despite new competition in the HAE market.
- Non-GAAP operating profit reached $51.7 million, up 107% year-over-year, with the company maintaining a cash balance of $269 million.
- The U.S. market contributed 89% of total revenue, with management expressing confidence in upcoming pediatric HAE approval and pipeline developments.
- Analysts project full-year profitability with an EPS forecast of $0.43 for fiscal 2025, despite investor concerns over revenue shortfall.
Last Updated: 03/11/2025, 14:56
Read Full TranscriptCompare BCRX to Peers and Sector
Metrics to compare | BCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −180.6x | 22.0x | −0.6x | |
PEG Ratio | −1.95 | 0.33 | 0.00 | |
Price/Book | −4.1x | 3.7x | 2.6x | |
Price / LTM Sales | 2.6x | 3.1x | 3.2x | |
Upside (Analyst Target) | 159.0% | 50.6% | 41.8% | |
Fair Value Upside | Unlock | 3.1% | 5.1% | Unlock |
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.600
(+173.57% Upside)
Earnings
Latest Release
Nov 03, 2025
EPS / Forecast
0.16 / 0.05
Revenue / Forecast
159.10M / 162.97M
People Also Watch
FAQ
What Is the BioCryst (BCRX) Share Price Today?
The live BioCryst share price today is 7.530
What Stock Exchange Does BioCryst (BCRX) Trade On?
BioCryst is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for BioCryst?
The stock symbol (also called a 'ticker') for BioCryst is "BCRX."
What Is the Current BioCryst Market Cap?
As of today, BioCryst market capitalisation is 1.59B.
What Is BioCryst's (BCRX) Earnings Per Share (TTM)?
The BioCryst EPS is currently -0.05 (Trailing Twelve Months).
When Is the Next BioCryst Earnings Date?
BioCryst's next earnings report will be released on 25 Feb 2026.
Is BCRX a Buy or Sell From a Technical Analyst Perspective?
Based on today's BioCryst moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has BioCryst Stock Split?
BioCryst has split 0 times. (See the BCRX stock split history page for full effective split date and price information.)
How Many Employees Does BioCryst Have?
BioCryst has 580 employees.
What is the current trading status of BioCryst (BCRX)?
As of 24 Dec 2025, BioCryst (BCRX) is trading at a price of 7.530, with a previous close of 7.610. The stock has fluctuated within a day range of 7.445 to 7.640, while its 52-week range spans from 6.000 to 11.310.
What Is BioCryst (BCRX) Price Target According to Analysts?
The average 12-month price target for BioCryst is USD20.6, with a high estimate of USD32 and a low estimate of USD9. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +173.57% Upside potential.
What Is the BCRX Premarket Price?
BCRX's last pre-market stock price is 7.460. The pre-market share volume is 4,210.000, and the stock has decreased by -0.150, or -1.970%.
What Is the BCRX After Hours Price?
BCRX's last after hours stock price is 7.500, the stock has decreased by -0.030, or -0.400%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.